441 related articles for article (PubMed ID: 26232113)
21. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases.
Smith Sehdev AE; Sehdev PS; Kurman RJ
Am J Surg Pathol; 2003 Jun; 27(6):725-36. PubMed ID: 12766576
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
23. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
24. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
[TBL] [Abstract][Full Text] [Related]
25. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
26. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.
Ho CL; Kurman RJ; Dehari R; Wang TL; Shih IeM
Cancer Res; 2004 Oct; 64(19):6915-8. PubMed ID: 15466181
[TBL] [Abstract][Full Text] [Related]
27. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
28. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
29. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ
Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340
[TBL] [Abstract][Full Text] [Related]
30. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
31. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.
Kuo KT; Guan B; Feng Y; Mao TL; Chen X; Jinawath N; Wang Y; Kurman RJ; Shih IeM; Wang TL
Cancer Res; 2009 May; 69(9):4036-42. PubMed ID: 19383911
[TBL] [Abstract][Full Text] [Related]
32. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
[TBL] [Abstract][Full Text] [Related]
33. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
[TBL] [Abstract][Full Text] [Related]
34. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
Vang R; Shih IeM; Kurman RJ
Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
[TBL] [Abstract][Full Text] [Related]
35. Diverse tumorigenic pathways in ovarian serous carcinoma.
Singer G; Kurman RJ; Chang HW; Cho SK; Shih IeM
Am J Pathol; 2002 Apr; 160(4):1223-8. PubMed ID: 11943707
[TBL] [Abstract][Full Text] [Related]
36. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
[TBL] [Abstract][Full Text] [Related]
37. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
38. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
Kurman RJ
Ann Oncol; 2013 Dec; 24 Suppl 10():x16-21. PubMed ID: 24265397
[TBL] [Abstract][Full Text] [Related]
39. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
[TBL] [Abstract][Full Text] [Related]
40. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
